Many treatments that target beta-amyloid protein are experimental for Alzheimer's | I Advance Senior Care Skip to content Skip to navigation

Many treatments that target beta-amyloid protein are experimental for Alzheimer's

April 16, 2018
by I Advance Senior Care
| Reprints

One of the hallmarks of Alzheimer’s disease is the formation of protein plaques and tangles between nerve cells. These are made of so-called beta-amyloid fragments that stick together and accumulate between nerve cells, disrupting their function.

These beta-amyloid plaques are the focus of many experimental treatments that researchers are currently developing. Below is a list, compiled by Alzheimer's News Today, of the experimental treatments targeting beta-amyloid plaques. More information about each potential treatment is available by clicking on the name of the compound.

ABvac40

ABvac40 is an active vaccine being developed by Araclon Biotech.It consists of a fragment of beta-amyloid protein called beta-amyloid 40. It is designed to elicit an immune response against beta-amyloid plaques.

ACI-24

ACI-24 is a liposome vaccine, being developed by AC Immune. It is based on a fragment of beta-amyloid protein called Aβ-15. It is designed to elicit an antibody response against aggregated beta-amyloid peptides.

Aducanumab

Aducanumab (BIIB037) is a monoclonal antibody being developed by Biogen against aggregated forms of beta-amyloid.

For the full list of experimental treatments, including Gantenerumab, Neflamapimod, and PQ912, visit Alzheimer's News Today.

Topics